{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:11:33Z","timestamp":1765545093063,"version":"3.48.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Eosinophilic Esophagitis (EoE) is a chronic immune-mediated disorder characterized by eosinophil infiltration into the esophageal mucosa. These changes lead to symptoms such as dysphagia, food impaction, and abdominal pain. Although less common, eosinophilic gastritis (EoG) shares similar inflammatory mechanisms but has fewer randomized controlled trials (RCTs) supporting treatment efficacy. Conventional treatments often fail to achieve histologic remission, whereas biological therapies targeting type 2 (T2) inflammation show promising results. This systematic review and meta-analysis evaluate the efficacy and safety of monoclonal antibodies in EoE, with a systematic review of EoG studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted using PRISMA guidelines to assess the efficacy and safety of monoclonal antibodies in EoE and EoG. Thorough searches were conducted across PubMed, Cochrane, and Embase up to June 2025. Primary outcomes were changed in Peak Eosinophilic Count, and secondary outcomes were endoscopic reference score (EREFS), overall adverse events, and serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eight RCTs having 865 participants with EoE, treated with 6 monoclonal antibodies, were included in the meta-analysis, and 3 additional RCTs (155 participants) with EoG were included in the systematic review but not the meta-analysis. Quality assessment using the Cochrane RoB 2 tool showed overall low risk of bias. Monoclonal antibodies significantly reduced peak eosinophil count, MD was \u201359.17 [95% CI: (\u221288.88, \u221229.45)], and improved EREFS. Dupilimab showed the strongest efficacy among the 6 antibodies evaluated, and the adverse events were comparable to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Monoclonal antibodies, particularly dupilumab, demonstrate efficacy in reducing peak eosinophil count and improving EREFS in EoE, with a favorable safety profile. Although the systematic review of EoG studies suggests similar trends, the limited number of RCTs precludes conducting a meta-analysis. Small sample sizes, lack of patient-reported outcomes, and high heterogeneity highlight the need for larger, standardized trials to confirm these findings and to assess long-term effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcg.0000000000002249","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T19:00:19Z","timestamp":1758135619000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal Antibodies for Eosinophilic Esophagitis and Gastritis"],"prefix":"10.1097","volume":"60","author":[{"given":"Qunoot","family":"Irfan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-2548","authenticated-orcid":false,"given":"Syed Muhammad Mehdi","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Hassan","family":"Alvi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nevada, Reno, Nevada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal Abid","family":"Hayat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loveeza","family":"Usman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabee","family":"Danish","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Arsalan","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"R1-20251212","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cgh.2024.09.031","article-title":"Prevalence and costs of eosinophilic esophagitis in the United States","volume":"23","author":"Thel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R2-20251212","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1573396315666191004110549","article-title":"Eosinophilic esophagitis in children: clinical findings and diagnostic approach","volume":"16","author":"De Matteis","year":"2020","journal-title":"Curr Pediatr Rev"},{"key":"R3-20251212","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/CEG.S364994","article-title":"The risk of esophageal food impaction in eosinophilic esophagitis patients: the role of clinical and socioeconomic factors","volume":"15","author":"Alhmoud","year":"2022","journal-title":"Clin Exp Gastroenterol"},{"key":"R4-20251212","first-page":"522","article-title":"Eosinophilic gastrointestinal diseases beyond the esophagus: an evolving field and nomenclature","volume":"18","author":"Redd","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"R5-20251212","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the agree conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"R6-20251212","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3390\/cells12202473","article-title":"Mechanistic insights into eosinophilic esophagitis: therapies targeting pathophysiological mechanisms","volume":"12","author":"Massironi","year":"2023","journal-title":"Cells"},{"key":"R7-20251212","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/apt.14123","article-title":"Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis","volume":"46","author":"Moawad","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20251212","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/cea.14196","article-title":"Eosinophilic esophagitis: Immune mechanisms and therapeutic targets","volume":"52","author":"Khokhar","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"R9-20251212","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaci.2018.05.018","article-title":"Biological therapies for eosinophilic gastrointestinal diseases","volume":"142","author":"Wechsler","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R10-20251212","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","article-title":"Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age","volume":"390","author":"Chehade","year":"2024","journal-title":"N Engl J Med"},{"key":"R11-20251212","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20251212","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"R13-20251212","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1136\/gutjnl-2023-330337","article-title":"Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"72","author":"Dellon","year":"2023","journal-title":"Gut"},{"key":"R14-20251212","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"R15-20251212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"R16-20251212","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(23)00145-0","article-title":"Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Kliewer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R17-20251212","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R18-20251212","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S2468-1253(23)00204-2","article-title":"Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebocontrolled, phase 3 trial","volume":"8","author":"Rothenberg","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R19-20251212","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","article-title":"Eosinophil depletion with benralizumab for eosinophilic esophagitis","volume":"390","author":"Rothenberg","year":"2024","journal-title":"N Engl J Med"},{"key":"R20-20251212","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"R21-20251212","first-page":"335","article-title":"Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European","volume":"5","author":"Lucendo","year":"2017","journal-title":"Gastroenterol J"},{"key":"R22-20251212","first-page":"437","article-title":"Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?","volume":"86","author":"Walgraeve","year":"2023","journal-title":"Acta Gastroenterol Belg"},{"key":"R23-20251212","first-page":"131","article-title":"Adverse effects associated with proton pump inhibitor use","author":"Yibirin","year":"2021","journal-title":"Cureus"},{"key":"R24-20251212","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s10620-018-5045-0","article-title":"Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis","volume":"63","author":"Wang","year":"2018","journal-title":"Dig Dis Sci"},{"key":"R25-20251212","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"R26-20251212","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti- IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R27-20251212","doi-asserted-by":"crossref","first-page":"AB37","DOI":"10.1016\/j.jaci.2016.12.179","article-title":"Adverse reactions to humanized monoclonal antibodies","volume":"139","author":"Roa-Medellin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R28-20251212","first-page":"5","article-title":"The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"R29-20251212","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12890-024-02868-3","article-title":"Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review","volume":"24","author":"Murillo","year":"2024","journal-title":"BMC Pulm Med"},{"key":"R30-20251212","first-page":"101379","article-title":"Successful treatment of eosinophilic cystitis with benralizumab","volume":"33","author":"Cooke","year":"2020","journal-title":"Urol Case Rep"},{"key":"R31-20251212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2019.12.117","article-title":"Placebo\u2014to be or not to be? Are there really alternatives to placebo-controlled trials?","volume":"32","author":"Krol","year":"2020","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:00:38Z","timestamp":1765544438000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002249"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000002249","relation":{},"ISSN":["1539-2031"],"issn-type":[{"type":"electronic","value":"1539-2031"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"2025-02-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}